Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Pfizer Inc       

PFIZER INC
Mes dernières consult.
Most popular
  Report  
SummaryNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

Pfizer Inc. : Pfizer CEO 2011 Compensation Valued At $25 Million, Up 44% Vs 2010

share with twitter share with LinkedIn share with facebook
share via e-mail
0
03/15/2012 | 10:07pm CEST
  By Peter Loftus 
  Of  
 

Pfizer Inc. (>> Pfizer Inc.) Chief Executive Ian Read received compensation valued at $25 million for 2011, up 44% from 2010, largely reflecting his promotion to the drug maker's top executive post in December 2010.

Read's compensation also was based partly on Pfizer exceeding targets set by the board's compensation committee for 2011 revenue, adjusted earnings and cash flow from operations, according to a proxy statement filed Thursday with the U.S. Securities and Exchange Commission.

The compensation committee cited Read's role in pursuing divestitures of noncore businesses and in returning cash to shareholders through dividends and share repurchases. Pfizer shares rose 23.6% for 2011.

Read, 58 years old, took over as Pfizer CEO in December 2010 when Jeffrey Kindler unexpectedly left the company. Read added the title of chairman of the board in December 2011.

For 2011, several elements of Read's compensation increased considerably. Stock awards rose to $5.7 million from $2.7 million, while the value of option awards surged to $6.9 million from less than $1 million, according to the proxy.

Read's salary was $1.7 million and his non-equity incentive plan compensation was $3.5 million. Other elements of his compensation: $6.9 million change in pension value and non-qualified deferred compensation earnings, and $319,000 in all other compensation.

For 2012, Read's salary will increase to $1.75 million, Pfizer said in the proxy.

Read, who joined Pfizer in 1978, has accumulated pension benefits with a total present value of about $27.4 million. In addition, the aggregate balance of Read's non-qualified deferred compensation is $8.2 million.

Pfizer Chief Financial Officer Frank D'Amelio received total compensation valued at $7.7 million for 2011, versus $6.5 million in 2010. Mikael Dolsten, president of worldwide research and development, received 2011 compensation valued at $7 million, up from $5.9 million for 2010.

Pfizer also disclosed in its proxy that its board compensation committee has made certain changes in executive pay in response to a disappointing shareholder advisory vote on executive compensation at last year's annual meeting.

The company has modified the terms of performance share awards so that they'll align more closely with performance, and has provided more a detailed explanation of its performance metrics, according to the proxy.

The compensation committee attributed the disappointing advisory vote at last year's annual shareholder meeting to dissatisfaction with the separation agreement with Kindler in late 2010. That agreement included a cash severance payment of $4.5 million and other compensation.

-By Peter Loftus, Dow Jones Newswires; 215-982-5581; [email protected]

Stocks mentioned in the article : Pfizer Inc.
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on PFIZER INC
05/25PFIZER : Biosimilar RETACRIT® epoetin alfa-epbx Approved by U.S. FDA
AQ
05/25PFIZER : Roivant Expands Senior Leadership with Key Hires
AQ
05/25PFIZER : Investigators at Pfizer Report Findings in Breast Cancer (Real-world ev..
AQ
05/25PFIZER : Data from Pfizer Provide New Insights into Asthma (Proteomic analysis o..
AQ
05/25PFIZER : LYRICA® pregabalin Oral Solution CV Phase 3 Trial in Pediatric Epilepsy..
AQ
05/25The Heated Quest for Opioid Alternatives -2-
DJ
05/25The Heated Quest for Opioid Alternatives
DJ
05/25PFIZER : GEA and Perceptive Engineering – a partnership for the global pha..
AQ
05/25PFIZER : Merck, Pfizer power tumor profiling firm Strata to $26M round
AQ
05/25PFIZER : Anti-infectives play Iterum raises $80M in IPO
AQ
More news
News from SeekingAlpha
2015Tracking Prem Watsa's Fairfax Financial Holdings Portfolio - Q2 2015 Update 
2015Antibiotics Stocks To Benefit From 21st Century Cures Act 
2015ISIS PHARMA STOCK DROPS ON GOOD NEWS : Re-Evaluating The Bull Case 
2015DOW DOGS : 14.63% More Returns From 5 Lowest Priced As Of August 6 Per indexArb 
2015Pfizer's GL-2045 an Orphan Drug for CIDP 
Financials ($)
Sales 2018 54 391 M
EBIT 2018 20 753 M
Net income 2018 12 828 M
Debt 2018 21 840 M
Yield 2018 3,81%
P/E ratio 2018 15,98
P/E ratio 2019 15,21
EV / Sales 2018 4,26x
EV / Sales 2019 4,08x
Capitalization 210 B
Income Statement Evolution
Consensus
 
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 39,6 $
Spread / Average Target 10%
EPS Revisions
Managers
NameTitle
Ian C. Read Chairman & Chief Executive Officer
Albert Bourla Chief Operating Officer & Director
Frank A. D'Amelio Chief Financial Officer & EVP-Business Operations
Freda C. Lewis-Hall Chief Medical Officer & Executive Vice President
W. Don Cornwell Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
PFIZER INC209 941
JOHNSON & JOHNSON-11.45%327 893
PFIZER-1.16%209 941
NOVARTIS-6.94%193 872
ROCHE HOLDING LTD.-9.17%190 404
MERCK AND COMPANY5.08%159 078